Market Overview:
The global gene therapy market reached a value of US$ 3.77 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 9.5 Billion by 2027 exhibiting a growth rate (CAGR) of 15.60% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Gene therapy is a technique for preventing disease progression by modifying the expression of mutated genes or altering the biological properties of living cells for therapeutic use. It improves the ability of the body to fight against a wide range of diseases, such as cancer, diabetes, hemophilia, cystic fibrosis, heart disease, and acquired immunodeficiency syndrome (AIDS). Nowadays, a wide variety of gene therapy products are available worldwide, which include viral vectors, bacterial vectors, plasmid deoxyribonucleic acid (DNA), human gene-editing technology, and patient-derived cellular gene therapy.
www.imarcgroup.com
Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.
Gene Therapy Market Trends:
The growing prevalence of inherited diseases and acquired disorders, in confluence with easy access to healthcare facilities, represents one of the key factors catalyzing the demand for gene therapy to improve the quality of life of patients. Moreover, the rising cases of genetic disorders, such as muscular dystrophy and cystic fibrosis, in children and young adults are bolstering the market growth. In line with this, the increasing geriatric population, which is more susceptible to develop infectious diseases on account of inappropriate gene activity, is contributing to the market growth. Apart from this, the development of new gene therapy that offers a safer, non-addictive alternative to opioids in treating a broad range of chronic pain conditions, such as lower back pain and rare neuropathic pain disorders, is favoring the market growth. In addition, a large variety of therapeutic genes are under investigation, including tumor suppressor, anti-angiogenesis, inflammatory cytokine, and micro ribonucleic acid (RNA) genes. These genes can assist in treating cancer, leukemia, severe combined immune deficiency, and blindness caused by retinitis pigmentosa, which is anticipated to stimulate the growth of the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global gene therapy market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on gene type, vector type, delivery method and application.
Breakup by Gene Type:
- Antigen
- Cytokine
- Tumor Suppressor
- Suicide Gene
- Deficiency
- Growth Factors
- Receptors
- Others
Breakup by Vector Type:
- Viral Vector
- Adenoviruses
- Lentiviruses
- Retroviruses
- Adeno-Associated Virus
- Herpes Simplex Virus
- Poxvirus
- Vaccinia Virus
- Others
- Non-Viral Techniques
- Naked and Plasmid Vectors
- Gene Gun
- Electroporation
- Lipofection
- Others
Breakup by Delivery Method:
www.imarcgroup.com
Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.
- In-Vivo Gene Therapy
- Ex-Vivo Gene Therapy
Breakup by Application:
- Oncological Disorders
- Rare Diseases
- Cardiovascular Diseases
- Neurological Disorders
- Infectious Disease
- Others
Breakup by Region:
To get more information on the regional analysis of this market, Request Sample
- North America
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abeona Therapeutics Inc., Adaptimmune Therapeutics plc, Adverum Biotechnologies Inc., Amgen Inc., Astellas Pharma Inc., Biogen Inc., Bluebird Bio Inc., Mustang Bio Inc. (Fortress Biotech Inc.), Novartis AG, Orchard Therapeutics plc, UniQure N.V. and Voyager Therapeutics Inc.
Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2021 |
Historical Period |
2016-2021 |
Forecast Period |
2022-2027 |
Units |
US$ Billion |
Segment Coverage |
Gene Type, Vector Type, Delivery Method, Application, Region |
Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered |
Abeona Therapeutics Inc., Adaptimmune Therapeutics plc, Adverum Biotechnologies Inc., Amgen Inc., Astellas Pharma Inc., Biogen Inc., Bluebird Bio Inc., Mustang Bio Inc. (Fortress Biotech Inc.), Novartis AG, Orchard Therapeutics plc, UniQure N.V. and Voyager Therapeutics Inc. |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |